Loading…
Loading…
2VSA.F does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 2VSA.F and 80,000+ other tickers.
See exactly how 2VSA.F's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 2VSA.F and 80,000+ other tickers.
Verastem, Inc. is a biopharmaceutical firm in its development phase, concentrating on the advancement and market introduction of therapeutic agents for oncological conditions. A primary investigational compound is VS-6766 (also known as avutometinib). This agent functions as a RAF/MEK clamp, impeding MEK kinase activity and the capacity of RAF to phosphorylate MEK. Its pipeline includes RAMP 201, an adaptive, two-part, multicenter, parallel cohort, randomized, open-label clinical trial. This study assesses the effectiveness and safety of avutometinib, both as a standalone treatment and in…
No recent news available.